Company: DVAX
Filing Date: 2025-05-12
Form Type: DEFA14A
Source: 0000930413-25-001704
Chunk: 7

Company: DYNAVAX TECHNOLOGIES CORP
Filing Date: 2025-05-12
Form: DEFA14A
Chunk 7
---
ological or immunological substance that is combined with a specific protein (antigen) in a vaccine t o h elp stimulate an immune response against the antigen. 2 Net of $100mm in cash and cash equivalents returned to stockholders via accelerate share repurchase program executed in Novem be r 2024. While many companies were reducing their workforces during the pandemic, we invested in our field sales team, which lay the groundwork for our rapid market growth following ACIP’s recommendation for universal adult vaccinations against hepatitis B in April 2022 2

ibdroot \ projects \ IBD - NY \ dilates2022 \ 698484_1 \ Presentations \ 24. 2025.02.XX Fight Deck \ FINAL - to share with Cooley \ Dynavax Investor Presentation (May - 2025)_Print.pptx z Opportunity: CpG 1018 adjuvant may improve Shingles vaccine tolerability while maintaining efficacy due to ability to generate high levels of CD4+ T cell responses Next Milestone: Phase 2 Topline data Q3 2025 Z We Are Progressing a Promising Clinical Vaccine Pipeline Powered by our Differentiated CpG Adjuvant © Copyright DYNAVAX 2025 Source: Factset; Wall Street Research 8 | Shingles Plague Feb 21, 2025 TD Cowen “We think the data demonstrates that Dynavax has a viable candidate that could offer a better tolerability profile and capture a meaningful portion of this multibillion - dollar market” Opportunity: CpG 1018 adjuvant with rF1V plague vaccine may improve the durability of protection with fewer doses administered over a shorter time period Next Milestone: Initiate Phase 2 trial in partnership with U.S. DoD in Q3 2025 Shingles vaccine represents opportunity to disrupt a large global market (Shingrix: ~$4.2B net sales in ’24) CpG 1018 drives differentiated efficacy in our proprietary vaccine HEPLISAV - B and our pipeline candidates Z Pandemic Influenza Z Lyme Disease Opportunity: CpG 1018 in an adjuvanted pandemic influenza vaccine to support global pandemic preparedness and response efforts Next Milestone: Initiate Phase 1/2 trial in Q2 2025 Opportunity: Investigational multivalent protein subunit vaccine adjuvanted with CpG 1018 to amplify immune response and improve durability Next Milestone: Initiate clinical development in 2027